Effect of formulation additives upon the intranasal bioavailability of a peptide drug: tetracosactide (ACTH1-24).
Nasal absorption of tetracosactide (ACTH1-24; Synacthen) was evaluated in anesthetized rats and compared to intravenous and intramuscular (i.m.) administration. The effect of formulation additives on tetracosactide bioavailability was studied following modification of nasal saline solution. Poloxamer 407 (Pluronic F-127) was used as a vehicle for drug sustained release, whereas sodium glycocholate and bacitracin were used as enhancers. Tetracosactide plasma levels were monitored with radioimmunoassay. Nasal bioavailability was low (4.4%) compared to i.m. (24%). Poloxamer 407 addition did not improve drug kinetics profiles and showed a non-significant decrease in bioavailability (4%). On the other hand, both enhancers effectively increased tetracosactide nasal absorption. The sodium glycocholate effect was very fast (Tmax = 5 min), but did not last long. Moreover, absorption was increased threefold compared to the simple formulation. On the other hand, maximum tetracosactide levels in plasma were reached after 15 min for the formulation containing bacitracin as enhancer, and tetracosactide bioavailability was strongly increased, to 24%, i.e., as much as after an i.m. injection.
Wüthrich
P
P
School of Pharmacy, University of Geneva, Switzerland.
Martenet
M
M
Buri
P
P
D000042:Absorption; D000281:Administration, Intranasal; D000818:Animals; D001414:Bacitracin / Q000737:chemistry; D001682:Biological Availability; D003366:Cosyntropin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D003692:Delayed-Action Preparations; D006000:Glycocholic Acid / Q000737:chemistry; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008297:Male; D014677:Pharmaceutical Vehicles; D011060:Poloxalene / Q000737:chemistry; D051381:Rats
D003692:Delayed-Action Preparations; D014677:Pharmaceutical Vehicles; D001414:Bacitracin; D003366:Cosyntropin; D011060:Poloxalene; D006000:Glycocholic Acid